1 / 6

A Descriptive Overview & Upstream Considerations

A Descriptive Overview & Upstream Considerations. Presented by: Michael Allen Daniel Demsey Avanthi Williams. Regulatory Considerations. Process Definition Scrutinized by regulatory authorities for safety and reliability Product Consistency

piper-jacobs
Download Presentation

A Descriptive Overview & Upstream Considerations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Descriptive Overview&Upstream Considerations Presented by: Michael Allen Daniel Demsey Avanthi Williams

  2. Regulatory Considerations • Process Definition • Scrutinized by regulatory authorities for safety and reliability • Product Consistency • Minimal variance in biochemical properties of product

  3. Regulatory Considerations • Cell Lineage • Origin of cell line • Health of donor • Recombination methods used (viral vectors) • Cell Line Stability • Across number of generations from cell bank to finished product

  4. Cell Line Selection Criteria • Capability to produce high product titers in the selected manufacturing process • Ability to produce a consistent product with uniform characteristics • Speed at which a high yielding cell line can be obtained

  5. Potential Cell Lines • Murine Hybridoma • Human Anti-Mouse Antibody (HAMA) response • Recombinant Mouse Cells • Transformed Human Cells • EBV-transformed human lymphoblastoid cells used to produce the anti-D antibody • Prevents hemolytic disease in infants Tumour cell Antigen Antibody-producing cloned hybridomas Monoclonal antibodies Isolated/immunized antibody-forming cell Hybridomas

  6. Cell Banking • Master Cell Bank (MCB) • Cryopreservation • Enough for life of process • Working Cell Bank (WCB) • Cryopreservation • Made from MCB Inoculate

More Related